Indivior PLC (NASDAQ:INDV) Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. lessened its stake in Indivior PLC (NASDAQ:INDV - Free Report) by 85.3% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 64,790 shares of the company's stock after selling 376,955 shares during the period. JPMorgan Chase & Co.'s holdings in Indivior were worth $805,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in INDV. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Indivior in the fourth quarter valued at approximately $56,000. Stifel Financial Corp acquired a new stake in Indivior during the 3rd quarter worth approximately $100,000. Jane Street Group LLC purchased a new position in Indivior in the 3rd quarter valued at approximately $180,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Indivior in the fourth quarter worth $359,000. Finally, Hennion & Walsh Asset Management Inc. purchased a new stake in shares of Indivior during the fourth quarter worth $1,192,000. Hedge funds and other institutional investors own 60.33% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently commented on INDV. Piper Sandler lowered their target price on Indivior from $16.00 to $13.00 and set an "overweight" rating for the company in a research note on Thursday, March 6th. Rodman & Renshaw started coverage on shares of Indivior in a research note on Tuesday, January 28th. They set a "buy" rating and a $16.00 target price on the stock. Finally, RODMAN&RENSHAW upgraded shares of Indivior to a "strong-buy" rating in a research note on Tuesday, January 28th.

Indivior Stock Performance

Shares of NASDAQ:INDV traded up $0.43 on Friday, hitting $11.98. 914,871 shares of the company's stock were exchanged, compared to its average volume of 985,869. Indivior PLC has a 1-year low of $7.33 and a 1-year high of $18.59. The company has a market capitalization of $1.65 billion, a PE ratio of -34.23 and a beta of 0.93. The firm's 50-day moving average is $9.75 and its 200 day moving average is $10.45.

Indivior (NASDAQ:INDV - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The company reported $0.41 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.22 by $0.19. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. The firm had revenue of $266.00 million during the quarter, compared to the consensus estimate of $240.13 million. On average, analysts anticipate that Indivior PLC will post 1.22 EPS for the current fiscal year.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.